Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fosun Pharma
Pharma
Takeda, AZ-Daiichi, Fosun-Henlius—Fierce Pharma Asia
Takeda's R&D chief explained his new investment priorities. AZ and Daiichi's TROP2 ADC cleared the FDA. Fosun failed to buy out Henlius. And more.
Angus Liu
Jan 24, 2025 8:55am
Henlius Biotech shareholders reject proposed takeover by Fosun
Jan 22, 2025 12:09pm
Daiichi, Fosun, Yuhan and more—Fierce Pharma Asia
Sep 27, 2024 10:15am
Gilead's Kite exits China cell therapy JV with Fosun Pharma
Sep 19, 2024 4:23pm
Daiichi-Merck, Wegovy, Takeda CEO—Fierce Pharma Asia
Jun 28, 2024 8:40am
AstraZeneca, BeiGene, Coherus—Fierce Pharma Asia
Dec 1, 2023 8:34am
